Good morning. My name is Chris, and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Phibro Animal Health Corporation Q4 2022 conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question during this time, simply press star then the number one on your telephone keypad. To withdraw your question, please press star one again. Thank you. Damian Finio, Chief Financial Officer, you may begin. Thank you, Chris, and good morning and welcome to the Phibro Animal Health Corporation earnings call for our Q4 and year ended June 30, 2022. My name is Damian Finio, and I am the Chief Financial Officer of Phibro. I'm joined on today's call by Jack Bendheim, Phibro's Chairman, President, and Chief Executive Officer, and Daniel Bendheim, Director and Executive Vice President of Corporate Strategy. On today's call, we will cover financial performance for the Q4 and our full fiscal year ending June 30, 2022, and provide financial guidance for our fiscal year ending June 30, 2023. At the conclusion of our opening remarks, we will open the lines for questions. I'd like to remind you that we are providing a simultaneous webcast of this call on our website, www.pahc.com. Also, on the investor section of our website, you will find copies of the earnings press release and annual report on Form 10-K filed with the SEC yesterday, as well as the transcript and slides presented on this call. Our remarks today will include forward-looking statements, and actual results could differ materially from those projections. For a list and description of certain factors that could cause results to differ, I refer you to the forward-looking statement section in our earnings press release. Our remarks include references to certain financial measures which were not prepared in accordance with generally accepted accounting principles or U.S. GAAP. I refer you to the non-GAAP financial information section in our earnings press release for a discussion of these measures. Reconciliations of these non-GAAP financial measures to the most directly comparable U.S. GAAP measures are included in the financial tables that accompany the earnings press release. We present our results on a GAAP basis and on an adjusted basis. Our adjusted results exclude acquisition related items, unusual, non-operational, or non-recurring items, including stock-based compensation and restructuring costs, other income expense as separately reported in the consolidated statements of operations, including foreign currency gains and losses net, and lastly, income tax effects related to pre-tax adjustments and unusual or non-recurring income tax items. Now, let me introduce our Chairman, President, and Chief Executive Officer, Jack Bendheim, to share his opening remarks which will include his perspective on the Q4, full year financial performance, and guidance for our fiscal year 2023. Jack. Thank you, Damian, and hello, everyone. I am pleased to share that our Q4 and full year performance reflected top and bottom line growth on an adjusted basis versus the respective prior periods. Net sales for the quarter were up 16% versus a year ago, our full year sales were up 13%. What's most impressive is that each of our three business segments posted double-digit year-over-year percentage growth, reflecting strong demand for our product portfolio. Adjusted EBITDA for the quarter was up 17%, while full year adjusted EBITDA was up 3%. Despite our strong financial results, our industry faces macroeconomic and operational challenges. The consequences of COVID-19 still linger, which has helped to fuel global macroeconomic headwinds leading to significant inflation. For our customers, this translates into higher feed, energy, and fertilizer prices, which in turn drives higher food prices for consumers. At Phibro, this means higher raw material and labor costs, which puts pressure on our margins despite increasing prices. We continue to work through supply challenges and labor shortages. Overall, the company managed well through another challenging year, and our strong performance reflects the efforts of our loyal employees. In response to higher input costs, we raised prices, but Phibro continues to act in other ways as well. Internally, we are addressing the impact of high input costs head on by identifying production efficiencies requiring investments in capital improvements. We will continue to drive efficiencies within our business by working collaboratively across business segments and geographic regions, leveraging our economies of scale where possible. As we look ahead, we are anticipating further year-over-year top and bottom line growth on an adjusted basis in fiscal 2023, with net sales projected to be in the range of $960 million-$1 billion, and adjusted EBITDA projections in the range of $113 million-$118 million, reflecting 2%-6% growth in both key financial measures. In the face of these challenges, it's important that we continue to keep our eye on the future. I'm excited that in addition to our existing projects, our companion animal development pipeline now includes a gene therapy opportunity targeting MVD in canines. Back in June, we announced this opportunity to the market, highlighting a collaboration for the development and commercialization of gene therapy with our partner, Rejuvenate Bio. They expect a positive initial approval as early as calendar year 2023. We're looking forward to progressing these projects and the prospects they add to our medium-term outlook. Overall, it was another challenging year, but we posted a solid Q4 and a full fiscal year strong financial performance. With that, I will ask Damian to go through our actual results and projections in more detail before opening the line for questions. Damian. Okay. Thank you, Jack. Let me start with our consolidated financial performance for the Q4 ended June 30, 2022 versus the same quarter one year ago. On a consolidated basis, Q4 net sales increased $35 million or 16% driven by growth in all three of our business segments, namely Animal Health, Mineral Nutrition, and Performance Products. GAAP-based net income and diluted EPS both declined 56% versus the same quarter a year ago. The decreases were driven primarily by increased foreign currency losses of $8.3 million and a $5.9 million increase in provision for income taxes, offset partially by $3.7 million more in operating income and $0.8 million less of interest expense. After making adjustments to our GAAP results, which include acquisition-related adjustments, foreign currency movements, and one-offs, Q4 adjusted EBITDA, adjusted net income, and adjusted diluted EPS were up 17%, 13%, and 13% respectively, driven by higher Animal Health revenue and gross profit as well as stronger Mineral Nutrition gross profit, partially offset by increased selling, general, and administrative expenses. On Slide 6, looking at the same financial metrics but now for the full year. On a consolidated basis, our full year financial performance improved over the prior year. Net sales increased $109 million or 13% driven again by growth across all three business segments, Animal Health, Mineral Nutrition, and Performance Products. GAAP-based net income and diluted EPS for the full year declined 10% versus the prior year, driven by increases in the provision for income taxes and selling and general administrative expenses offset by improved operating profits, less interest expense and foreign currency gains. After adjusting GAAP results for one-off acquisition-related items and foreign currency movements, adjusted EBITDA improved 3% driven by sales and gross profit growth, offset by an increase in strategic initiatives, while adjusted net income and adjusted diluted EPS improved 4% driven by higher gross profit on higher sales, offset partially by increases in SG&A costs driven by incremental strategic investments. Turning to business segment performance on slide 7, starting with the Q4 financial performance of our largest segment, Animal Health, which is comprised of the MFAs and other Nutritional Specialties and vaccine product categories. Net sales increased $20 million or 13% versus the same quarter prior year. The increase in our Animal Health segment net sales was driven by improvements in all product categories. First, a 12% increase in MFAs and others versus the prior quarter, driven by higher average selling prices and increased sales of processing aids used in the ethanol fermentation industry. Second, a 15% improvement in nutritional specialties net sales driven by strong domestic demand in dairy, growth in the Asia-Pacific region, and strong demand for our companion animal product, Rejensa. Third, a 19% improvement in vaccine net sales driven by strong demand across all regions. In terms of profitability, Animal Health Adjusted EBITDA was $33.5 million, an increase of $4 million or 14% over the prior year quarter, while Adjusted EBITDA margin was flat. The improvement was driven by the increase in revenues and resulting gross profit, offset partially by an increase in selling, general, and administrative expenses. Moving to slide 8, which reflects full-year financial performance for our Animal Health segment. Net sales were up $61 million or 11% versus the prior year. The increase in Animal Health full-year net sales was driven by a 10% increase in MFAs and other versus the prior year, primarily due to increased demand for MFAs, particularly in the Latin America and Canada region, coupled with strong demand for processing aids used in the ethanol fermentation industry. Also, 10% growth in Nutritional Specialties driven by strong international and domestic demand, particularly for dairy, coupled with growth in our companion animal product, Rejensa. Lastly, a 21% increase in vaccine net sales driven by strong demand in most regions. In terms of profitability, Animal Health Adjusted EBITDA for the year was $124 million, which was consistent with the prior year, while the Adjusted EBITDA margin declined 230 basis points as stronger sales and gross profits were offset by higher selling, general and administrative expenses, reflecting the impact of higher than typical inflation and the macroeconomic headwinds mentioned previously. Moving on to Q4 financial performance for our other segments on slide 9. Let's start with Mineral Nutrition. Net sales for the Q4 was $69.4 million, an increase of 22% versus the same quarter prior year, driven by higher average pricing of trace minerals. Mineral Nutrition Adjusted EBIT of $6.7 million, an increase of 44%, driven by increased gross profit. The Adjusted EBITDA margin for the quarter was 9.6%, an improvement of 150 basis points versus a year ago. Moving to our Performance Products segment, we finished the year strong with net sales of $19.3 million for the three months ended June 30, 2022, reflecting an increase of 16% over the prior year's same quarter, driven by strong demand and pricing for copper-based products, as well as strong demand for ingredients used in personal care products. The increased demand drove Adjusted EBITDA of $2.4 million for the quarter, a 5% improvement versus the same quarter prior year, while the Adjusted EBITDA margin declined 100 basis points to 12.3%. Lastly, corporate expenses increased 17% from $1.6 million versus the same quarter prior year, primarily driven by an increase in investments relating to strategic initiatives. Now, looking at full-year financial performance for these segments on Slide 10. Mineral Nutrition net sales for the full year were $260 million, an increase of 18% versus the prior year, driven by higher selling prices of trace minerals. Mineral Nutrition Adjusted EBITDA was $24 million, an increase of 40%, driven by increased gross profit on favorable product mix. Adjusted EBITDA margin for the quarter was 9.3%, an improvement of 150 basis points versus one year ago. Turning to full fiscal year results for our Performance Products segment, net sales was $76 million, an increase of 13% over the prior year, driven by strong demand for ingredients used in personal care products and strong demand and favorable pricing of copper-based products. However, Adjusted EBITDA of $8.7 million represents a decline of 8% and was driven by higher raw material and production costs versus the prior year. Consequently, Adjusted EBITDA margin declined 270 basis points to 11.5%. Lastly, corporate expenses increased $3 million or 7% versus the prior year. The increase was driven primarily by an increase in investments relating to strategic initiatives. I'll discuss our projections for fiscal year 2023 momentarily, but it's worth mentioning now that we intend to continue investing in the company's future despite the pressure that the macroeconomic environment is putting on margins. Corporate expenses will increase again this coming year. Turning to key capitalization-related metrics on slide 11. On a trailing 12-month basis, free cash flow was -$5 million as capital expenditures exceeded operating cash flow generated by the business. As discussed on previous calls, we have been intentionally building inventory levels to both support our top-line growth, but also to better manage supply chain disruptions. However, because of the effects of inflation, it's more expensive to replace those inventories as they are depleted, thus consuming cash. To free up more cash, we are placing even more attention on monitoring inventory levels and leveraging our economies of scale to drive more competitive freight costs. Of course, given these inflationary times, this will be a challenge, but our anticipation is that free cash flow will improve going forward. Moving on, our gross leverage ratio was 3.9 times at June 30th. This is calculated by dividing total debt of $434 million by trailing twelve-month Adjusted EBITDA of $111 million. Want to note that we use net debt and Adjusted EBITDA as defined by our existing loan agreement to calculate the net leverage ratio used for covenant compliance purposes. In terms of liquidity, we had $194 million available at year-end. This includes cash and short-term investments of $91 million and $103 million of unused and available revolving credit. The accessibility of available revolving credit is subject to leverage ratio limitations outlined in the loan agreement. Lastly, consistent with the past several quarters, we announced a quarterly dividend of $0.12 per share or $4.9 million. That concludes our perspective on both Q4 and full-year financial performance. Let's turn our attention to the outlook for fiscal year 2023. Please turn to the financial guidance shown on slide 12. For fiscal year 2023, largely driven by strong demand for our products across all regions, coupled with the annualization of price increases taken in fiscal year 2022, we are projecting consolidated net sales in the range of $960 million-$1 billion, which reflects a year-over-year growth rate of approximately 2%-6%. Underpinning these consolidated top-line projections is the assumption that we can grow our largest segment, Animal Health, by 3%-7%, which is driven by anticipated double-digit percentage growth of Nutritional Specialties as we continue to drive the use of Direct-Fed Microbials and further increases in the sales of Rejensa, our companion animal product, as well as healthy growth of our other two Animal Health product categories, vaccines and MFAs and other. For our other business segments, namely Mineral Nutrition and Performance Products, we are projecting flat to low single-digit% sales growth as the sales of these segments directly correlate to the underlying cost of raw materials. We have seen indications that customers are managing their inventory levels to help combat the incremental costs of inflation. Despite the pressure on margins, we are steadfast in our commitment to continue investing in the company's future. We are planning $37 million of investments in strategic initiatives, an increase of $8 million over fiscal year 2022. This includes, but is not limited to, investments in our companion animal development pipeline, African swine fever, continued registration of products in new markets, and the ongoing build-out of our newest vaccine production facility in Sligo, Ireland. We also intend to spend $39 million on capital improvements, which is an increase of $2 million over fiscal year 2022. This includes, but is not limited to, a significant investment in our large production facility in Quincy, Illinois, which will increase manufacturing capacity and in turn lower projected per unit costs, expanding vaccine manufacturing capacity at several locations and completing efficiency projects at our facilities in Israel. As such, with the annualization of price increases and actions taken to manage costs, we are projecting Adjusted EBITDA in the range of $113 million-$118 million, which also reflects a growth rate of 2%-6%. On a GAAP basis, net income and diluted earnings per share are projected to be flat or declining by up to 8%, largely dependent on movement in our tax provisions, including uncertain tax positions, often referred to as FIN 48 reserves, as well as movements in foreign currencies. For adjusted net income and adjusted diluted earnings per share, we are projecting a decline of 2% at the low end of the range and an improvement of 5% at the high end. In terms of our adjusted effective tax rate, we are projecting a rate of about 30%, which is in line with our actual adjusted effective tax rate in fiscal year 2022 and 2021. Lastly, consistent with last year's quarterly trends, we expect a seasonal-driven decline in our upcoming Q1 net sales and Adjusted EBITDA relative to the Q4 of fiscal year 2022, with quarter-on-quarter improvement as we progress through fiscal year 2023. In summary, our fiscal year 2023 financial guidance is as follows: net sales of approximately $960 million-$1 billion, reflecting growth of 2%-6%. On a GAAP basis, net income of approximately $45-$49 million and diluted earnings per share of $1.11-$1.21. Adjusted EBITDA of approximately $113-$118 million, reflecting growth of 2%-6%. Adjusted net income of approximately $52 million-$56 million and adjusted diluted EPS of approximately $1.28-$1.38, reflecting a year-over-year 2% decline on the low end of the range or 5% growth on the high end. An adjusted effective tax rate of 30%, which is comparable to the 29.5% actual effective tax rate for fiscal years 2022 and 2021. Overall, we had a strong Q4, posted net sales and Adjusted EBITDA performance improvements for both the quarter and the full year, and we are projecting further growth in fiscal year 2023. That concludes our opening remarks. Chris, could you please open the lines for questions? Certainly. As a reminder, if you'd like to ask a question, please press Star, then one on your telephone keypad. Our first question is from Michael Ryskin with Bank of America. Your line is open. Hi, good morning. This is John Kim on for Mike. I wanted to ask on the Rejensa, could you give us a bit more color on how things have trended compared to your expectation of doubling sales in 2022 in the current inflationary environment? If you could update us on what your high-level outlook is for 2023 and long term, that'd be great. Hey, John. This is Daniel Bendheim. Thanks for the question. So last year, Rejensa, as we guided towards doubling sales year-over-year, and we achieved that. Embedded in this year's guidance is that we're looking to double sales again. You know, I do think that we have seen a little bit of slowness at the vet, that, other companies have recorded as well. Rejensa has the advantage of still being in early innings. Despite the fact that there might be a little bit of a macro slowdown, there's plenty of opportunity for us, and we are seeing our momentum continue to build, and we feel pretty good about that number for the year. Great. On African swine fever, do you have any expectations or what are your expectations for fiscal 2023 on that in China? Well, as you know from everything you follow, African swine fever has not been solved. T he Chinese have done a much better job in biosecurity. The problem exists both in China, in the Far East and interestingly, seeing it more and more in Europe, in some of the wild pigs that are being caught. The potential of outbreaks are there all over the place. So far there has not been a vaccine developed. We're continuing on developing of our vaccine. It's been difficult, I think as maybe we said before, to get our people into China, I would say not just difficult, impossible, because of the COVID restrictions. It slowed down our development, but we continue to remain optimistic that we have a solution to the problem and as we continue to develop. Thank you. Appreciate that. Again, that's star one to ask a question. The next question is from Erin Wright with Morgan Stanley. Your line is open. Hi, everybody. This is Justin Wang on for Erin. Thanks for the questions. We were wondering if you can go over the underlying livestock market trends across the varying geographies, especially for the U.S., for the Animal Health business and what you're seeing there. I have a follow-up. That's a short question, but it requires hours of answers. Overall, what we're seeing around the world is a strong livestock business. A s you know, from what you're reading, our prices are up across the board in sort of every market, and the consumers continue to pay the prices. We're not seeing a slowdown, and that's reflected in our sales, again, across the world, across the markets we're in. T here are unusual factors that you have to add to this thing, which is increasing drought in the United States. On the cattle side, there is an increase in slaughter. There's less animals raised on grass and more in the feedlots. As you can understand, the nature of all of our businesses, the more on feedlots, the better it is. That might come to an end six months or a year from now. You can't tell. Again, it's a global business, so what we see reflected in the U.S. might be reflected in a different way down in Brazil. As I said, based on what we're seeing in our sales and the markets we're in, business for the animal health industry continues to be good. Okay. That's helpful. Thank you. Just on the guidance here, what does your guide currently assume in terms of price realizations for the year? We were wondering if you could speak a little bit more on the incremental investments that you're making for the year and what that entails. Thanks. All right. Thanks for the question, Justin. I can take that one. In terms of our guidance, as I mentioned, sales 2%-6% growth next year. There's really two parts to that, continued strong demand across all segments and region, and then the annualization of the fiscal year 2022 price increases. We'll see a full year of that in 2023. If you remember last year we spoke, I think it was the Q2, maybe it was the Q1 earnings call, we said that we took pricing action. The pricing action lagged the cost increases. We expected most of that in the second half of fiscal year 2022, which ended up being true. Our margins going forward in fiscal year 2023 are consistent with what we realized in the actual numbers in fiscal year 2022. If you think about that implies that the price increases that we've taken and the annualization of those in fiscal year 2023 are keeping up with the cost increases. In terms of the strategic investments that you mentioned, again, some of those will continue to be reported in the corporate business segment. There's a pretty good spread across different types of projects, so I would say it's a diverse portfolio. Most of the concentration is in our three growth drivers for fiscal year 2023 in the medium term, which is vaccines, companion animals, and nutritional specialties. Thank you very much. I appreciate that. We have no further questions at this time. I'll turn it over to Mr. Finio for any closing remarks. All right. Thank you, Chris. I wanna reiterate what Jack said to start the call, which is a thank you again to our employees for enabling Phibro to achieve such strong financial performance in fiscal year 2022. We appreciate you taking the time today to join our call and for your continued interest in Phibro Animal Health Corporation. On behalf of Jack, Donny, the rest of the executive management team, we are excited about the opportunities that fiscal year 2023 presents and the investments that we're making in our future. We hope you enjoy these last days of summer. Thanks again, and have a great rest of your day. Ladies and gentlemen, this concludes today's conference call. Thank you for participating. You may now disconnect.